Compare Stocks: NTRB, ACB, BIOA, and IKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.49	$3.85	$2.56 ▼ $6.36	$295.10M	0.63	1.12 million shs	1.35 million shs
BIOA BioAge Labs	$6.34	$8.96	$5.04 ▼ $25.95	$290.99M	1.08	916,955 shs	667,337 shs
IKT Inhibikase Therapeutics	$1.97	$2.30	$1.33 ▼ $2.61	$274.89M	0.89	607,851 shs	435,034 shs
NTRB Nutriband	$6.65	$5.53	$2.80 ▼ $9.19	$80.86M	1.92	132,723 shs	45,139 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+14.54%	+20.05%	+68.16%	-15.28%
BIOA BioAge Labs	0.00%	-4.08%	-25.32%	-70.89%	+18.50%
IKT Inhibikase Therapeutics	0.00%	-1.50%	-15.81%	+0.51%	+22.36%
NTRB Nutriband	0.00%	-8.65%	-4.45%	+126.19%	-11.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.49	$3.85	$2.56 ▼ $6.36	$295.10M	0.63	1.12 million shs	1.35 million shs
BIOA BioAge Labs	$6.34	$8.96	$5.04 ▼ $25.95	$290.99M	1.08	916,955 shs	667,337 shs
IKT Inhibikase Therapeutics	$1.97	$2.30	$1.33 ▼ $2.61	$274.89M	0.89	607,851 shs	435,034 shs
NTRB Nutriband	$6.65	$5.53	$2.80 ▼ $9.19	$80.86M	1.92	132,723 shs	45,139 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+14.54%	+20.05%	+68.16%	-15.28%
BIOA BioAge Labs	0.00%	-4.08%	-25.32%	-70.89%	+18.50%
IKT Inhibikase Therapeutics	0.00%	-1.50%	-15.81%	+0.51%	+22.36%
NTRB Nutriband	0.00%	-8.65%	-4.45%	+126.19%	-11.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.00	Hold	N/A	N/A
BIOA BioAge Labs	2.63	Moderate Buy	$33.00	420.50% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	174.11% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest NTRB, ACB, BIOA, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/11/2026	BIOA BioAge Labs	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$8.00
10/8/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
10/5/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/2/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/28/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/16/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/9/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/8/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/7/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$314.07M	0.94	$0.70 per share	6.40	$6.27 per share	0.72
BIOA BioAge Labs	$10.36M	28.10	N/A	N/A	$7.59 per share	0.84
IKT Inhibikase Therapeutics	$260K	1,057.28	N/A	N/A	$2.30 per share	0.86
NTRB Nutriband	$2.04M	39.64	N/A	N/A	$0.55 per share	12.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	74.83	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
NTRB Nutriband	-$8.23M	-$0.53	N/A	N/A	N/A	-430.35%	-109.07%	-95.54%	12/7/2026 (Estimated)

Latest NTRB, ACB, BIOA, and IKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q2 2027	ACB Aurora Cannabis	-$0.03	N/A	N/A	N/A	$50.68 million	N/A
9/4/2026	Q2 2027	NTRB Nutriband	N/A	-$0.07	N/A	-$0.07	N/A	$0.44 million
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
BIOA BioAge Labs	N/A	17.19	17.19
IKT Inhibikase Therapeutics	N/A	15.82	15.82
NTRB Nutriband	N/A	4.21	4.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
BIOA BioAge Labs	N/A
IKT Inhibikase Therapeutics	3.81%
NTRB Nutriband	19.70%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
BIOA BioAge Labs	17.55%
IKT Inhibikase Therapeutics	7.10%
NTRB Nutriband	52.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	65.72 million	65.72 million	Optionable
BIOA BioAge Labs	62	45.90 million	37.84 million	N/A
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
NTRB Nutriband	3	12.16 million	5.81 million	Not Optionable

NTRB, ACB, BIOA, and IKT Headlines

Recent News About These Companies

Nutriband Seeks New Patent Protection For AVERSA Transdermal Technology

October 8, 2026 | rttnews.com

Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology

October 8, 2026 | globenewswire.com

Nutriband Inc.: Nutriband Marks Five Years on Nasdaq - CEO Letter to Shareholders

October 2, 2026 | finanznachrichten.de

Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders

October 1, 2026 | globenewswire.com

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Featured in Documentary Examining U.S. Opioid Crisis

September 29, 2026 | financialcontent.comF

Nutriband CEO Gareth Sheridan Featured in Documentary on Opioid Crisis and Abuse-Deterrent Innovation

September 29, 2026 | quiverquant.comQ

Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis

September 29, 2026 | globenewswire.com

Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert

September 25, 2026 | financialcontent.comF

Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board

September 25, 2026 | markets.businessinsider.com

Nutriband warrants to expire Sept. 30 at $6.43 strike price

September 22, 2026 | streetinsider.com

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

September 22, 2026 | globenewswire.com

Nutriband CEO Gareth Sheridan to Attend Inaugural Nasdaq LaB Biotech Summit

September 9, 2026 | quiverquant.comQ

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

September 9, 2026 | globenewswire.com

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

September 8, 2026 | globenewswire.com

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

August 13, 2026 | globenewswire.com

Nutriband shareholders approve proposals and expand board leadership

June 23, 2026 | theglobeandmail.com

Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference

May 15, 2026 | globenewswire.com

Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

April 22, 2026 | globenewswire.com

Nutriband Advances Lead Abuse-Deterrent Fentanyl Patch Branding

April 7, 2026 | tipranks.com

Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

March 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NTRB, ACB, BIOA, and IKT Company Descriptions

Aurora Cannabis NASDAQ:ACB

$4.49 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.49 0.00 (0.00%)

As of 07:00 AM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

BioAge Labs NASDAQ:BIOA

$6.34 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.45 +0.11 (+1.78%)

As of 07:18 AM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Inhibikase Therapeutics NASDAQ:IKT

$1.97 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.97 0.00 (-0.05%)

As of 07:00 AM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Nutriband NASDAQ:NTRB

$6.65 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.63 -0.02 (-0.36%)

As of 07:32 AM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTRB, ACB, BIOA, and IKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTRB, ACB, BIOA, and IKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTRB, ACB, BIOA, and IKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NTRB, ACB, BIOA, and IKT Company Descriptions

Aurora Cannabis NASDAQ:ACB

BioAge Labs NASDAQ:BIOA

Inhibikase Therapeutics NASDAQ:IKT

Nutriband NASDAQ:NTRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTRB, ACB, BIOA, and IKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTRB, ACB, BIOA, and IKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTRB, ACB, BIOA, and IKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NTRB, ACB, BIOA, and IKT Company Descriptions

Aurora Cannabis NASDAQ:ACB

BioAge Labs NASDAQ:BIOA

Inhibikase Therapeutics NASDAQ:IKT

Nutriband NASDAQ:NTRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools